BRPI0515628A - composto de 2-morfolina-4-pirimidona - Google Patents

composto de 2-morfolina-4-pirimidona

Info

Publication number
BRPI0515628A
BRPI0515628A BRPI0515628-9A BRPI0515628A BRPI0515628A BR PI0515628 A BRPI0515628 A BR PI0515628A BR PI0515628 A BRPI0515628 A BR PI0515628A BR PI0515628 A BRPI0515628 A BR PI0515628A
Authority
BR
Brazil
Prior art keywords
alkyl
morpholine
integer
disease
compound
Prior art date
Application number
BRPI0515628-9A
Other languages
English (en)
Inventor
Kazutoshi Watanabe
Fumiaki Uehara
Shinsuke Hiki
Toshiyuki Kohara
Kenji Fukunaga
Satoshi Yokoshima
Original Assignee
Mitsubishi Pharma Corp
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Pharma Corp, Sanofi Aventis filed Critical Mitsubishi Pharma Corp
Publication of BRPI0515628A publication Critical patent/BRPI0515628A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

COMPOSTO DE 2-MORPOLINA-4-PIRIMIDONA Um composto representado pela fórmula (1), seu isómero ativo oticamente, ou seu sal aceitável farmaceuticamente: em que X representa CH ou N; 1 representa um C~ 1~-C~ 12~ alquil; R¬ 2¬ representa um átomo de hidrogênio, ou similar; R<39> representa um C~ 1-C~ 6~ alquil ou similar; q representa 0 ou um inteiro de 1 a 7; Y representa um C~ 1~-C~ 6~ alquil ou similar; p representa 0 ou um inteiro de 1 a 5; R representa um 2,3-dihidroindolil ou similar, que é usado para tratamento preventivo e/ou terapêutico de uma doença causada pela proteína tau quinase 1 (por exemplo, doença de Alzheimer).
BRPI0515628-9A 2004-09-09 2005-09-09 composto de 2-morfolina-4-pirimidona BRPI0515628A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004296926 2004-09-09
PCT/JP2005/017080 WO2006028290A1 (en) 2004-09-09 2005-09-09 2-morpholino-4-pyrimidone compound

Publications (1)

Publication Number Publication Date
BRPI0515628A true BRPI0515628A (pt) 2008-03-04

Family

ID=35385631

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0515628-9A BRPI0515628A (pt) 2004-09-09 2005-09-09 composto de 2-morfolina-4-pirimidona

Country Status (17)

Country Link
US (1) US8106045B2 (pt)
EP (3) EP1789414A1 (pt)
JP (1) JP5060287B2 (pt)
KR (1) KR20070058586A (pt)
CN (1) CN101035781A (pt)
AR (1) AR050865A1 (pt)
AU (1) AU2005280885B2 (pt)
BR (1) BRPI0515628A (pt)
CA (1) CA2578434A1 (pt)
EA (1) EA013839B1 (pt)
IL (1) IL181732A0 (pt)
MX (1) MX2007002807A (pt)
NO (1) NO20071787L (pt)
NZ (1) NZ554300A (pt)
TW (1) TW200621760A (pt)
WO (1) WO2006028290A1 (pt)
ZA (1) ZA200702266B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200740779A (en) * 2005-07-22 2007-11-01 Mitsubishi Pharma Corp Intermediate compound for synthesizing pharmaceutical agent and production method thereof
TW200813015A (en) * 2006-03-15 2008-03-16 Mitsubishi Pharma Corp 2-(cyclic amino)-pyrimidone derivatives
MX2009001913A (es) * 2006-08-23 2009-03-06 Pfizer Prod Inc Compuestos de pirimidona como inhibidores de gsk-3.
WO2008026046A1 (en) * 2006-08-30 2008-03-06 Pfizer Products Inc. Morpholine d3 dopamine antagonists
AR064660A1 (es) * 2006-12-26 2009-04-15 Mitsubishi Tanabe Pharma Corp Derivados de pirimidinona 6-heterociclica 2-sustituida, medicamentos que los contienen y usos para prevenir y/o tratar enfermedades neurodegenerativas entre otras
CN101835750B (zh) 2007-08-22 2013-07-17 阿斯利康(瑞典)有限公司 环丙基酰胺衍生物
EP2193129B1 (en) * 2007-09-14 2012-10-24 Mitsubishi Tanabe Pharma Corporation 6-pyrimidinyl-pyrimid-2-one derivative
DE102008010363A1 (de) * 2008-02-18 2009-08-20 Lang, Florian, Prof. Dr.med. Sgk1 als therapeutisches und diagnostisches Target für karzinomatöse Erkrankungen
TW201039825A (en) 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
EP2464632A1 (en) * 2009-08-13 2012-06-20 Mitsubishi Tanabe Pharma Corporation Pyrimidone derivatives used as tau protein kinase 1 inhibitors
EP2464639A1 (en) * 2009-08-13 2012-06-20 Mitsubishi Tanabe Pharma Corporation Pyrimidone derivatives used as tau protein kinase 1 inhibitors
CA2771822C (en) 2009-09-04 2020-08-11 Daniel A. Erlanson Bruton's tyrosine kinase inhibitors
US20110201623A1 (en) 2010-02-18 2011-08-18 Uczynski Michael A Crystalline Form Of A Cyclopropyl Benzamide Derivative
JP5784110B2 (ja) * 2010-05-11 2015-09-24 サノフイ 置換されたｎ−ヘテロアリールテトラヒドロ−イソキノリン誘導体、その製造及び治療上の使用
US8802673B2 (en) 2011-03-24 2014-08-12 Hoffmann-La Roche Inc Heterocyclic amine derivatives
US9029370B2 (en) * 2011-06-10 2015-05-12 Hoffmann-La Roche Inc. Substituted benzamide derivatives
AR091273A1 (es) 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
CU20130027A7 (es) 2013-02-28 2014-10-30 Ct De Neurociencias De Cuba Chaperoninas químicas como nuevos moduladores moleculares de la beta agregación proteica presente en las enfermedades conformacionales
CN104974017B (zh) * 2014-04-09 2017-11-17 上海医药工业研究院 (1r,2s)‑2‑(3,4‑二氟苯基)环丙胺·d‑扁桃酸盐的制备方法
SG11201900515PA (en) 2016-07-21 2019-02-27 Biogen Ma Inc Succinate forms and compositions of bruton's tyrosine kinase inhibitors
CN108299252A (zh) * 2018-04-04 2018-07-20 梯尔希（南京）药物研发有限公司 一种去甲肾上腺素磺酸类代谢物的合成方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2116460A1 (en) 1993-03-02 1994-09-03 Mitsubishi Chemical Corporation Preventive or therapeutic agents for alzheimer's disease, a screening method of alzheimer's disease and tau-protein kinase i originated from human being
TWI241298B (en) 1998-09-25 2005-10-11 Mitsubishi Chem Corp Pyrimidone derivatives
AU2001262150A1 (en) * 2000-03-23 2001-10-03 Mitsubishi Pharma Corporation 2-(nitrogen-heterocyclic)pyrimidone derivatives
EP1136482A1 (en) * 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors
MXPA04002661A (es) * 2001-09-21 2004-11-22 Sanofi Aventis Derivados de pirimidona 4, 3-sustituida.
ES2323576T3 (es) * 2001-09-21 2009-07-21 Mitsubishi Tanabe Pharma Corporation Derivados de 4-pirimidona 3-sustituida.
CN1726209B (zh) 2002-12-16 2011-04-13 三菱制药株式会社 3-取代的-4-嘧啶酮衍生物
TWI357408B (en) * 2003-03-26 2012-02-01 Mitsubishi Tanabe Pharma Corp 3-substituted-4-pyrimidone derivatives
JP5186213B2 (ja) * 2004-09-29 2013-04-17 田辺三菱製薬株式会社 タウプロテインキナーゼ１阻害剤としての６−ピリジニル−４−ピリミドン誘導体

Also Published As

Publication number Publication date
EP1789414A1 (en) 2007-05-30
AU2005280885A1 (en) 2006-03-16
AU2005280885B2 (en) 2011-09-22
EA200700572A1 (ru) 2007-10-26
US8106045B2 (en) 2012-01-31
IL181732A0 (en) 2007-07-04
AR050865A1 (es) 2006-11-29
JP2008512347A (ja) 2008-04-24
NZ554300A (en) 2009-12-24
US20090124618A1 (en) 2009-05-14
MX2007002807A (es) 2007-05-16
WO2006028290A1 (en) 2006-03-16
JP5060287B2 (ja) 2012-10-31
NO20071787L (no) 2007-05-09
EP2266979A1 (en) 2010-12-29
KR20070058586A (ko) 2007-06-08
EP2258701A1 (en) 2010-12-08
CA2578434A1 (en) 2006-03-16
TW200621760A (en) 2006-07-01
ZA200702266B (en) 2008-09-25
CN101035781A (zh) 2007-09-12
EA013839B1 (ru) 2010-08-30

Similar Documents

Publication Publication Date Title
BRPI0513433A (pt) derivados de hidantoìna para o tratamento de distúrbios inflamatórios
MA31084B1 (fr) Derives de piperidine agonistes de gpcr
MA29261B1 (fr) Derives de (1,5-diphenyl-1h-pyrazol-3-yl)oxadiazole, leur preparation et leur application en therapeutique
ATE356621T1 (de) (s)-2-n-propylamino-5-hydroxytetralin als d3- agonistisches therapeutikum
NO20071787L (no) 2-morfolin-4-pyrimidonforbindelse
BRPI0515851A (pt) composto de pirimidona
UY29919A1 (es) Derivados sustituidos de 3,4-dihidroisoquinolin-1-amino-trifluoroacetato, sus composiciones farmacéuticas y aplicaciones
EA200600971A1 (ru) Применение замещённых 2 - аминотетралинов для профилактического лечения болезни паркинсона
UY30274A1 (es) Derivados sustituidos de la n-(4-metil-1,3-tiazol-2-il)guanidina, formulaciones farmacéuticas conteniéndolo y aplicaciones
BR0312729A (pt) Novos derivados de indol-3-enxofre
CY1111481T1 (el) Υποκατεστημενα αρυλοκυκλοπροπυλακεταμιδια ως ενεργοποιητες γλυκοκινασης
BRPI0511504A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, e, agente preventivo ou terapêutico para uma doença resultante de beta-amilóides
EA200870358A1 (ru) 2-(циклический амино) пиримидоновые производные в качестве ингибиторов tpk1
BRPI0610312B8 (pt) dispositivo de assistência à caminhada
EA200970637A1 (ru) 2-замещенные-6-гетероциклилпроизводные пиримидона в качестве ингибиторов тау-протеинкиназы
EA201070366A1 (ru) 3-метил-2-((2s)-2-(4-(3-метил-1,2,4-оксадиазол-5-ил)фенил)морфолино)-6-(пиримидин-4-ил)пиримидин-4(3н)-он в качестве ингибитора тау-протеинкиназы
BR112012027387A2 (pt) composição para controle de doenças de plantas e uso da mesma
EA201070367A1 (ru) Производное 6-пиримидинилпиримид-4-она
BRPI0417844A (pt) derivados de amida contendo um substituinte de ciclopropilaminocarbonila, de utilidade como inibidores de citocina
BRPI0510221A (pt) composto de aril cetona, composição, forma de dosagem unitária, uso da composição e método para preparar uma composição
NO20080860L (no) Substituert propanamidderivat og farmasoytisk preparat som inneholder dette
DK1634595T3 (da) N-Phenylbenzamidderivater som medikamenter til behandling af kronisk obstruktiv lungesygdom (KOL)
EA200800071A1 (ru) Производные бензофуранила как ингибиторы 5-нт6-рецептора
EA200970615A1 (ru) Соединения имидазолидинониламинопиримидина для лечения рака
DE602006012079D1 (de) Isothiazolopyridin-3-ylenamine zur bekämpfung tierischer schädlinge

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2257 DE 08/04/2014.